發(fā)布時(shí)間：2018-10-24 17:50

【摘要】：目的觀察同步放化療后紫龍金片維持治療對(duì)局部晚期非小細(xì)胞肺癌(non-small cell lung cancer,NSCLC)的療效及生活質(zhì)量的影響。方法 66例經(jīng)同步放化療后取得緩解或穩(wěn)定的局部晚期NSCLC患者,按隨機(jī)數(shù)字表法分為治療組和對(duì)照組,每組33例。治療組給予紫龍金片(0.65 g/片),每次4片,每日3次,服藥至疾病進(jìn)展或無(wú)法耐受;對(duì)照組給予安慰劑,每次4片,每日3次。統(tǒng)計(jì)分析兩組患者的無(wú)疾病進(jìn)展生存期,1、2年生存率及生活質(zhì)量的改變。結(jié)果試驗(yàn)過(guò)程中有4例脫落,62例可評(píng)價(jià)療效,治療組30例,對(duì)照組32例。治療組和對(duì)照組的無(wú)進(jìn)展生存期(progression free survival,PFS)分別為9.20個(gè)月、6.23個(gè)月,兩組比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05);1年生存率治療組為73.0%,優(yōu)于對(duì)照組的51.7%(P0.05);治療組和對(duì)照組2年生存率分別為52.0%、48.6%,兩組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);與對(duì)照組比較,治療組軀體、角色、社會(huì)功能領(lǐng)域及總健康狀況得分升高,乏力、呼吸困難及咳嗽得分下降(P0.05),治療組神疲乏力、少氣懶言、頭暈眼花、食欲不振、咳嗽、自汗癥狀改善(P0.05);兩組患者的不良反應(yīng)均在可接受范圍內(nèi)。結(jié)論紫龍金片維持治療局部晚期NSCLC安全有效,可延長(zhǎng)患者的無(wú)進(jìn)展生存期及1年生存率,改善局部晚期NSCLC的中醫(yī)癥狀,提高患者的生活質(zhì)量。
[Abstract]:Objective to observe the effect of Zilongjin tablet maintenance therapy on local advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC) after simultaneous radiotherapy and chemotherapy. Methods 66 patients with locally advanced NSCLC who had achieved remission or stability after simultaneous radiotherapy and chemotherapy were divided into treatment group (n = 33) and control group (n = 33). The treatment group was given Zilongjin tablet (0.65 g / tablet), 4 tablets per day, 3 times a day, until the disease progressed or intolerable, while the control group was given placebo, 4 tablets per day, 3 times a day. The progression-free survival time, 1-and 2-year survival rate and quality of life were statistically analyzed in both groups. Results there were 4 cases of shedding in the course of the experiment, 62 cases could be evaluated, 30 cases in the treatment group and 32 cases in the control group. The progressive survival time (progression free survival,PFS) of the treatment group and the control group were 9.20 months and 6.23 months, respectively. The 1-year survival rate in the treatment group was 73.0, which was higher than that in the control group (51.7%, P0.05); the 2-year survival rate in the treatment group and the control group was 52.0 and 48.6, respectively. There was no significant difference between the two groups (P0.05); compared with the control group, the body and role of the treatment group were significantly higher than that of the control group. The scores of social function field and general health state increased, fatigue, dyspnea and cough decreased (P0.05). The symptoms of self-sweating were improved (P0.05); the adverse reactions of both groups were within acceptable range. Conclusion Zilongjin tablet is safe and effective in the treatment of local advanced NSCLC. It can prolong the progression-free survival time and 1-year survival rate, improve the TCM symptoms of local advanced NSCLC and improve the quality of life of the patients.
【作者單位】： 浙江省紹興市人民醫(yī)院放療科;
【基金】：浙江省中醫(yī)藥科技計(jì)劃資助項(xiàng)目(No.2012ZB160)
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 汪江;顏維仁;;紫龍金片配合化療治療中晚期非小細(xì)胞肺癌的研究[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2008年01期

，

本文編號(hào)：2292103